The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

COVID-19 Clinical Trial

Official title:

A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04312997
• Other study ID #: PUL-042-502
• Status: Completed
• Phase: Phase 2
• Start date: June 16, 2020
• Est. completion date: July 2, 2021

Study information

• Verified date: March 2023
• Source: Pulmotect, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Adults who have tested positive for SARS-CoV-2 infection and who may require supplemental oxygen will receive PUL-042 Inhalation Solution or placebo 3 times over a one week period in addition to their normal care. Subjects will be be followed and assessed for their clinical status over 28 days to see if PUL-042 Inhalation Solution improves the clinical outcome

Recruitment information / eligibility

• Status: Completed
• Enrollment: 101
• Est. completion date: July 2, 2021
• Est. primary completion date: July 2, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects must have a positive test for SARS-CoV-2.

2. COVID-19 signs and symptoms such as (fever, cough, shortness of breath or fatigue) with onset within the 7 days prior to Screening

3. Subjects should be Ordinal Scale for Clinical Improvement score of 4 or less.

4. Subjects receiving oxygen should have pulse oximetry = 93% on 3 liters per minute of oxygen or less delivered by nasal prongs.

5. Subjects can be receiving standard of care (SOC) for COVID-19, this includes marketed therapies or therapies with Emergency Use Authorization (EUA) for COVID-19 treatment.

6. Subject's spirometry (FEV1 and forced vital capacity [FVC]) must be =70% of predicted value.

7. If female, the subject must be surgically sterile or = 1 year postmenopausal. If of child-bearing potential (including being < 1years postmenopausal) and, if participating in sexual activity that may lead to pregnancy, the subject agrees to use an effective dual method of birth control (acceptable methods include intrauterine device, spermicide, barrier, male partner surgical sterilization, and hormonal contraception) during the study and through 30 days after completion of the study.

8. If female, must not be pregnant, plan to become pregnant, or nurse a child during the study and through 30 days after completion of the study. A pregnancy test must be negative at the Screening Visit, prior to dosing on Day 1.

9. If male, must be surgically sterile or, if not surgically sterile and if participating in sexual activities that may lead to pregnancy, be willing to practice two effective methods of birth control (acceptable methods include barrier, spermicide, or female partner surgical sterilization) during the study and through 30 days after completion of the study.

10. Must have the ability to understand and give informed consent.

Exclusion Criteria:

1. No documented infection with SARS-CoV-2.

2. Patients who are in respiratory distress or require high flow oxygen, non-invasive ventilation or mechanical ventilation (Ordinal Scale for Clinical Improvement >4) or with pulse oximetry less than 93% on oxygen with a flow rate of 3 liters per minute or less by nasal prongs at the time of screening.

3. Known history of chronic pulmonary disease (e.g., asthma [including atopic asthma, exercise-induced asthma, or asthma triggered by respiratory infection], chronic pulmonary disease, pulmonary fibrosis, COPD), pulmonary hypertension, or heart failure.

4. Exposure to any investigational therapy (defined as any agent not currently marketed or without EUA) at the time of or within 30 days prior to the Screening Visit.

5. Any condition which, in the opinion of the Principal Investigator, would prevent full participation in this trial or would interfere with the evaluation of trial endpoints

Related Conditions & MeSH terms

• COVID-19

Intervention

Drug:
• PUL-042 Inhalation Solution
20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)
• Placebo
Sterile saline for inhalation

Locations

Country	Name	City	State
United States	Ascension St. John	Bartlesville	Oklahoma
United States	Clinical Research of South Florida Alliance for Multispecialty Research	Coral Gables	Florida
United States	St. Elizabeth Healthcare	Edgewood	Kentucky
United States	Invesclinic US LLC	Fort Lauderdale	Florida
United States	MD Anderson Cancer Center	Houston	Texas
United States	Next Level Urgent Care	Houston	Texas
United States	University of California Irvine	Orange	California
United States	Premeir Urgent Care of California	San Bernardino	California
United States	DBC Research Corp.	Tamarac	Florida
United States	Affinity Clinical Research, LLC	Tampa	Florida
United States	Ascension St. John	Tulsa	Oklahoma

Sponsors (2)

Lead Sponsor	Collaborator
Pulmotect, Inc.	United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Worsening of COVID-19 Within 28 Days	To determine the efficacy of PUL-042 Inhalation Solution in decreasing the severity of COVID-19 in subjects: 1) who have documented SARS-CoV-2 infection, and 2) if receiving oxygen, should have pulse oximetry = 93% on 3 liters per minute of oxygen or less delivered by nasal prongs (Ordinal Scale for Clinical Improvement 4 or less) at the time of enrollment.; The primary endpoint analysis is the evaluation of the number of patients with clinically meaningful worsening of COVID-19 within 28 days from the start of experimental therapy, as indicated by an increase of at least 2 points on the Ordinal Scale for Clinical Improvement (OSCI). The OSCI used in this study is derived from a draft scale proposed by the World Health Organization for clinical improvement. Higher values represent a worse outcome.; The OSCI is a nine-point scale (0-8) with 0 being no clinical or virological evidence of infection and 8 being death.	28 days
Secondary	Number of Participants With Positive SARS-CoV-2 Test Results at the End of Study	SARS-Co-V-2 positivity up to 28 days from the start of experimental therapy.	28 days
Secondary	Number of Participants With Worsening of COVID-19 Over 14 Days	To determine the difference in the proportion of COVID-19 patients with clinically meaningful worsening of COVID-19 within 14 days from the start of experimental therapy, as indicated by an increase of at least 2 points on the Ordinal Scale for Clinical Improvement (OSCI).; The OSCI is a nine-point scale (0-8) with 0 being no clinical or virological evidence of infection and 8 being death.	14 days
Secondary	Time to COVID-19 Symptom Improvement: Respiratory Symptoms	To assess the progression of COVID-19 severity during the study as measured by the SARS-CoV-2 Symptom Score.; The SARS-CoV-2 Symptom Score measures 3 elements on a 0-3 scale (cough, shortness of breath or difficulty breathing, and muscle aches or fatigue) ranging from 0 for none to 3 for severe. The fourth element is fever and it is rated on a 0-4 scale with 0 being no fever and 4 being life-threatening.; The time to respiratory symptom improvement is measured in days. Time to improvement of symptoms was prospectively defined as the time from an initial symptom score of =1 to a reduction of =1 point. The time to improvement of symptoms was evaluated for each individual symptom listed above.	28 days
Secondary	Time to Resolution of COVID-19 Symptoms	The time to resolution of COVID-19 symptoms during the study was measured by the SARS-CoV-2 Symptom Score: The SARS-CoV-2 Symptom Score measures 3 elements on a 0-3 scale (cough, shortness of breath or difficulty breathing, and muscle aches or fatigue) ranging from 0 for none to 3 for severe. The fourth element is fever and it is rated on a 0-4 scale with 0 being no fever and 4 being life-threatening.; The time to the first occurrence of resolution of symptoms (in days) was defined as the time from the first symptom score of =1 to a symptom score of 0.	28 days
Secondary	Number of Participants Requiring ICU Admission	The requirement for ICU admission within 28 days from the start of the experimental therapy.	28 days
Secondary	Number of Participants Requiring Mechanical Ventilation	The requirement for mechanical ventilation within 28 days from the start of the experimental therapy.	28 days
Secondary	Number of Participant Death	All-cause mortality at 28 days from the start of experimental therapy.	28 days